Axovant (AXGT) Prices 14.03M Share Common Offering at $3.75/Sh

Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced the pricing of its underwritten public offering of 14,031,336 of its common shares at a price to the public of $3.75 per share. In addition, and in lieu of common shares, Axovant is offering to certain investors pre-funded warrants to purchase 3,301,998 common shares at a purchase price of $3.74999 per pre-funded warrant, which represents the per share public offering price for the common shares, minus the $0.00001 per share exercise price of each such pre-funded warrant. The aggregate gross proceeds to Axovant from the offering are expected to be approximately $65 million before deducting underwriting discounts and commissions and offering expenses. All of the common shares and pre-funded warrants are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 2,600,000 of its common shares on the same terms and conditions. The offering is expected to close on February 24, 2020, subject to customary closing conditions.

SVB Leerink is acting as sole book-running manager for the offering. Chardan is acting as lead manager for the offering.

You May Also Be Interested In

• Aon plc (AON) files mixed shelf
• Jonathan Korngold resigns from Bumble board amid Blackstone departure
• Bending Spoons closes IPO, raises ~$954M on Nasdaq